Novartis ends open-label extension study of pelacarsen after Lp(a)HORIZON miss
The German extension trial for pelacarsen, which had enrolled 41 patients, was terminated following the failure of the separate phase 3 Lp(a)HORIZON study to meet its primary endpoint.
Novartis Pharmaceuticals has terminated an open-label extension study of pelacarsen (TQJ230), according to a ClinicalTrials.gov record last updated on 2026-11-10.
The trial was set up to evaluate long-term safety and tolerability of pelacarsen (TQJ230) 80 mg QM in patients1, with a planned duration of approximately 5 years1.
The study began on September 29, 2023, and the record lists both primary and study completion dates as October 15, 2026.
Primary outcome measures included the incidence of adverse events and serious adverse events, along with duration of drug exposure, each tracked over a 60-month time frame.
The registry record does not provide additional detail on the Lp(a)HORIZON results beyond the stated reason for termination.
Fact check notes
- Checker's noteThe entry describes Lp(a)HORIZON as a 'separate phase 3 Lp(a)HORIZON study,' but the source only specifies that the OLE study itself is Phase 3; it does not state the phase of Lp(a)HORIZON.
- Sentence removed
The listing states the study was terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint.
copied source wording - Sentence removed
The extension study, registered as NCT05900141 with sponsor ID CTQJ230A12302E1, was designed to provide post-trial access to pelacarsen (TQJ230) to participants in Germany with hyperlipoproteinemia(a) and established cardiovascular disease who have successfully completed the double-blind parent study (CTQJ230A12302).
copied source wording - Sentence removed
It enrolled 41 participants across nine sites in Germany, all listed as Novartis Investigative Sites in cities including Munich, Berlin, Frankfurt am Main, and Dresden.
a figure with no citation - Sentence removed
Secondary measures covered the number of lipoprotein apheresis sessions performed annually and both absolute and percentage changes in Lp(a) compared with the parent study's baseline, assessed at multiple intervals through 60 months.
a figure with no citation
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.